Skip to main content

Table 1 Characteristics of HIV-infected patients at initiation of antiretroviral therapy in ten African countries, 2010–2012 (N = 3579)

From: Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa

  Benin Burkina Faso Cameroon Cote d’Ivoire Kenya Senegal South Africa Togo Uganda Zambia
Number of sites 1 1 1 3 1 1 1 1 1 1
Cities Cotonou Bobo Dioulasso Limbé Abidjan Eldoret Dakar Stellenbosch Lomé Kampala Lusaka
Type of care Tertiary Tertiary Tertiary Primary / Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Primary
Number of patients included (proportion of total population followed) 300
(30%)
300
(21%)
298
(~30%)
900
(20%)
299
(1%)
297
(91%)
300
(16%)
300
(13%)
285
(7%)
300 (~10%)
Median age in years (IQR) 35 (30–42) 35 (30–42) 38 (32–44) 38 (33–45) 37 (32–44) 41 (35–49) 38 (33–46) 35 (30–43) 35 (28–42) 37 (31–42)
Female sex (%) 198 (66.0) 216 (72.0) 196 (65.8) 581 (64.6) 190 (63.5) 179 (60.3) 193 (64.3) 197 (65.7) 191 67.0) 162 (54.0)
Type of ART (%)
 2 NRTI +1 NNRTI 298 (99.3) 269 (89.7) 298 (100) 786 (87.3) 291 (97.3) 286 (96.3) 298 (99.3) 287 (95.7) 253 (88.8) 295 (98.3)
 3 NRTI 0 (0.0) 0 (0.0) 0 (0.0) 22 (2.5) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 2 NRTI +1 PI 2 (0.7) 31 (10.3) 0 (0.0) 92 (10.2) 8 (2.7) 9 (3.0) 2 (0.7) 13 (4.3) 32 (11.2) 5 (1.7)
TDF (%) 39 (13.0) 87 (29.0) 191 (64.1) 303 (33.7) 122 (40.8) 122 (41.1) 243 (81.0) 44 (14.7) 61 (21.4) 265 (88.3)
HBsAg-positivity (%) 5/35 (14.3) 16/76 (21.1) 2/12 (16.7) 10/37 (27.0) 0/2 (0.0) 25/135 (18.5) 13/279 (4.7) 6/30 (20.0) 4/94 (4.3) 7/59 (11.9)
  1. IQR: interquartile range, ART: antiretroviral therapy, NRTI: nucleoside reverse-transcriptase inhibitors, NNRTI: non-nucleoside reverse-transcriptase
  2. Inhibitors, PI: protease inhibitors, TDF: tenofovir; HBsAg: Hepatitis B surface antigen